Jan. 1 at 4:57 PM
$URGN 2024 net product revenue for JELMYTO was approximately
$90.4 M, showing strong year-over-year growth.
Full-year 2025 revenue is projected to reach
$94–
$98 M, with ZUSDURI ramping after FDA approval in mid-2025.
The launch of ZUSDURI provides a major growth catalyst, as it targets recurrent low-grade intermediate-risk NMIBC patients and expands UroGen’s commercial footprint.
The company has a cash position of roughly
$127–
$161 M, sufficient to support operations but requiring careful management due to ongoing operating losses.
Quarterly net losses remain around
$33 M, driven by commercial expansion and R&D investment.
Shares outstanding are approximately 50 M, accounting for potential dilution from options and warrants.
Peak combined sales of JELMYTO and ZUSDURI are expected to reach
$527 M annually by 2028.
Gross margins are assumed to be 70% at peak, consistent with specialty oncology pharmaceuticals.
